外科用ロボット市場調査

ロボット工学の分野は近年驚異的な進歩を遂げ、さまざまな業界に革新をもたらし、生産性を向上させています。特に、ロボット工学は外科用ロボットの開発と実装を通じてヘルスケアに大きな影響を与えています。

このため、外科用ロボットの市場調査は、急速に進化するこの業界の現在の傾向、新興技術、将来の可能性を理解する上で重要な役割を果たします。また、外科用ロボット市場の包括的な分析は、企業が情報に基づいた意思決定を行い、競争で優位に立つために不可欠になります。

現在のビジネス環境における手術ロボット市場調査の重要性

As the healthcare industry continues to evolve, the demand for more advanced and efficient surgical solutions has grown, paving the way for the rapid development and adoption of surgical robots. That’s why surgical robot market research is relevant for several stakeholders such as manufacturers, healthcare providers, investors, and policymakers; to understand and capitalize on the opportunities surgical robots present.

外科用ロボットの市場調査は、Intuitive Surgical、Stryker Corporation、Medtronic、Smith & Nephew、Zimmer Biomet などの企業が主導する市場で競争するために特に重要です。これらの企業は市場で強力な存在感を示し、幅広い製品ポートフォリオを持ち、研究開発に多大な投資を行っています。

In any case, some key reasons why surgical robot market research is growing so fast are the following:

• 市場動向の特定: 外科用ロボット業界の最新動向と技術の進歩に関する詳細な洞察を得ることは、企業が競争力を維持するために不可欠です。外科用ロボットの市場調査は、これらの動向を特定し、企業が医療提供者の進化するニーズを満たす革新的な製品とソリューションを開発できるようにすることを目的としています。
• 市場の動向を理解する: 外科用ロボット業界は、政府の規制や慢性疾患の蔓延などの要因によって制御されています。外科用ロボットの市場調査は、これらの要因に関する貴重な洞察を提供し、世界中の企業が十分な情報に基づいた意思決定を行うのに役立ちます。
• 市場の可能性を評価する: 外科用ロボットの市場調査は、企業がロボット外科ソリューションの市場規模、成長の可能性、将来の需要を把握するのに役立ちます。このデータは、市場での存在感を拡大し、この業界に投資したいと考えている企業にとって非常に重要です。
• 競合分析: 市場の主要企業、その製品提供、市場戦略を詳細に分析することで、企業が競合他社の強みと弱みを理解するのに役立ちます。
• 成長機会の特定: 外科用ロボットの市場調査は、企業が未開拓の市場、ニッチな分野、大きな成長の機会をもたらす可能性のある新しいアプリケーションを特定するのに役立ちます。

Surgical Robot Market Research: How Leading Medtech Firms Win the Next Adoption Curve

Surgical robot market research has shifted from sizing exercises to procedure-level intelligence. The buyers have changed. The economics have changed. The competitive set now includes platforms that did not exist a decade ago.

Hospital purchasing committees evaluate robotic platforms against capital budget pressure, surgeon preference, and procedure mix economics. Soft tissue, orthopedic, and spine segments each follow distinct adoption curves. Manufacturers that read those curves correctly capture installed base advantage. Those that read them through aggregate market reports end up second in every tender.

Why Surgical Robot Market Research Requires Procedure-Level Granularity

The conventional approach treats robotic surgery as a single market. The better approach segments by procedure economics. A robotic prostatectomy, a robotic knee arthroplasty, and a robotic bronchoscopy share almost nothing in reimbursement, surgeon learning curve, or capital justification logic.

Intuitive Surgical built its moat on prostatectomy and gynecology. Stryker’s Mako captured orthopedic share through preoperative CT planning and haptic feedback. Medtronic’s Hugo and Johnson & Johnson’s Ottava entered with modular architectures targeting general surgery and cost-sensitive geographies. CMR Surgical’s Versius positioned around portability for mid-volume hospitals. Each platform answers a different procurement question. Aggregate market sizing obscures that.

SIS International Research conducted structured expert interviews with surgeons, biomedical engineering directors, and supply chain leaders across South Korea, Brazil, Germany, and the United States to map purchase decision drivers for surgical robot systems. The pattern across geographies showed that case-cost economics, instrument cost-per-procedure, and OR throughput drove adoption far more than headline platform pricing.

The Decision Drivers That Actually Move Capital Committees

Surgeon advocacy starts the process. Finance ends it. Between them sit four variables that determine whether a platform reaches contract:

• Instrument and accessory cost per case. Disposable arm costs and reusable instrument life cycles determine the real margin on each procedure.
• OR turnover time. Setup, drape, and docking time compress daily case volume. A platform that adds twelve minutes per case loses two cases per day.
• Service contract structure. Uptime guarantees, software upgrade pathways, and consumable bundling shape five-year total cost of ownership.
• Surgeon training pipeline. Proctor availability, simulation hours, and case volume to proficiency determine ramp speed.

Aggregate reports rarely quantify these. Procedure-level primary research does. A KOL mapping exercise that interviews chief surgeons without interviewing OR nurses, sterile processing leads, and biomedical engineering misses the operational reality that kills deals after clinical approval.

Geographic Adoption Curves Diverge More Than Forecasts Suggest

Robotic surgery adoption in the United States, Western Europe, Japan, South Korea, China, and Brazil follows different curves shaped by reimbursement, hospital concentration, and domestic manufacturing policy.

China’s procurement reforms and volume-based purchasing pressure have accelerated demand for domestic platforms. Companies including Microport’s Toumai and Shanghai Fosun’s partnerships have used local manufacturing and pricing flexibility to enter tier-two and tier-three hospital tenders that imported platforms cannot reach on price. Guangzhou-based optical positioning suppliers have built component depth that supports a domestic robotic surgery supply chain independent of Western navigation vendors.

South Korea presents a different pattern. High surgeon density, concentrated tertiary hospital systems, and aggressive technology adoption create a market where procedure mix expansion matters more than unit pricing. Brazil’s private hospital networks anchor demand, while public-sector adoption depends on bundled service contracts that shift capital risk to the manufacturer.

In SIS International’s mixed-methodology engagements across Latin American healthcare, the gap between manufacturer-assumed adoption barriers and surgeon-reported adoption barriers consistently exceeded thirty percent, with reimbursement clarity and consumable supply reliability emerging as the underweighted variables in commercial planning.

Competitive Intelligence Beyond the Big Four

Strategy decks still center on Intuitive, Stryker, Medtronic, and J&J. The decisive competitive intelligence sits one layer below. Specialized platforms shape segment economics in ways the big four cannot match.

In spine, Globus Medical’s ExcelsiusGIN and Medtronic’s Mazor X compete on screw placement accuracy and intraoperative imaging integration. In orthopedics, Smith+Nephew’s CORI and Zimmer Biomet’s ROSA pressure Mako on capital cost and footprint. In flexible robotics, Johnson & Johnson’s Monarch and Intuitive’s Ion compete on peripheral lung biopsy economics. Navigation specialists including Brainlab and component suppliers such as ILUMARK supply the optical tracking and single-use marker infrastructure that platform vendors increasingly white-label.

Win/loss analysis at the tender level reveals what aggregate share data cannot: which platforms are winning new accounts, which are defending installed bases through service lock-in, and which are losing the surgeon-influencer battle inside academic medical centers.

An Intelligence Framework for Surgical Robot Market Research

Strategic clarity in this category requires four parallel intelligence streams:

Source: SIS International Research

Each stream answers a question the others cannot. Procedure economics tells you what to charge. Tender intelligence tells you how to sell. Adoption barrier mapping tells you what to build into the next platform release. Geographic assessment tells you where to deploy capital first.

What the Strongest Commercial Teams Do Differently

The medtech firms taking share in robotic surgery share three commercial habits. They commission primary research at the procedure level, not the platform level. They interview the full OR economic stakeholder set, not just surgeon champions. They refresh competitive intelligence on a tender-by-tender cadence rather than annual market reports.

Surgical robot market research conducted this way produces decisions that hold under capital committee scrutiny. It also produces the evidence base that supports premium pricing in a category where buyers have learned to discount manufacturer claims.

The platforms that will define the next decade of robotic surgery are being specified now in product roadmaps, regulatory submissions, and surgeon training partnerships. The intelligence that informs those specifications determines which platforms reach scale and which become footnotes.

SISインターナショナルについて

SISインターナショナル 定量的、定性的、戦略的な調査を提供します。意思決定のためのデータ、ツール、戦略、レポート、洞察を提供します。また、インタビュー、アンケート、フォーカス グループ、その他の市場調査方法やアプローチも実施します。 お問い合わせ 次の市場調査プロジェクトにご利用ください。